High Content Screening (HCS): A Global Strategic Business Report
San Jose, California (PRWEB) July 10, 2012
Follow us on LinkedIn – High content screening is an evolutionary drug discovery technology that is rapidly moving beyond the realm of virtual, future research to a result-oriented, present-day methodology that offers deeper insights into cell biology and early stage drug discovery and research. The growing user base and its increasing expectations are forecast to drive HCS into becoming a more sophisticated, easy-to-use, cost effective and a robust technology. Significant advances in automation, hardware and software, enabled cellular imaging is expected to expand into high throughput applications such as high content screening. HCS technology offers immense throughput and high data quantity enabled by advancements in robotics, instrumentation, image and data analysis software, storage and management tools. The technology is widely being used by academic research institutes, biotechnology and pharmaceutical companies in the drug discovery pipeline, including target identification, target verification, assay development, screening as well as secondary screening for toxicity testing.
Development of superior techniques for delivery of probes into targeted organelles or specific proteins and live cells is one of the key factors driving the kinetic and Live Cell Imaging market. The market is also driven by other factors such as improved reagents, better informatics and image analysis instruments, as well as novel fluorescent probes suited for live cell imaging applications. Increasing governmental stimulus worldwide for cell-based research is also forecast to be the key factor to push growth for the technology over the coming years.
Development of micro-environments, new reagents and continued autofluorescent protein application is expected to enhance means of quantifying cellular biology. Currently, there is a tremendous focus on the productivity aspect of HCS in both phases of information creation as well as its understanding. This is expected to complement the detection platforms, resulting in HCS becoming a routine data generation tool and a major part of the decision support activity in life science research. The focus in future would be on enhancing the relevance of biological data obtained through HCS by enabling screening of tissues, organisms, organs and multicellular assemblies, while the core HCS applications would enter the phase of mass usage. Incorporation of proteomics and genomics technologies into cellomics would also be a significant factor for future growth of the technology.
The last decade witnessed the evolution of HCS technology from being just an outgrowth of high throughput screening (HTS) into a more pragmatic technology with valuable utility across all activities in the drug discovery pipeline. HCS currently is enjoying a wide ranging adoption in key areas of life science research with major application areas being neurobiology, cell signaling, oncology, in vitro toxicology and target validation. HCS is considered a highly versatile tool in cytotoxicity measurements for analysis of acute cell toxicity through cell rounding and cell counting and more specific measurements of monitoring organelle health. HSC can lead the way for novel drug discovery procedures, with primary applications in the assessment of phospholipidosis for liver lipidosis, neurotoxicity during the developmental stage. In addition, developments in the HCS technology have made it possible to image and quantify neural morphology. Coupled with algorithmic approaches, HCS can be effectively used to study and monitor neurite outgrowth and neuronal protection. To date the technique has been successfully used to study various neurobiological disorders such as Huntington Disease, Alzheimer Disease, Brain Cancer, Parkinsons Disease, and Amyotrophic Lateral Sclerosis.
Developed markets of United States and Europe represent the largest regional markets worldwide, as stated by the new market research report on High Content Screening. The HCS marketplace in both US and Europe is peppered with large number of research organizations, diversified pharmaceutical companies, OEMs, research laboratories and institutes, each with their own agenda and purpose. Competition is typically intense and each player strives to differentiate its product/service offering through unique features, advanced technology and frequent product introductions and innovations. Established market leaders such as Thermo Scientific, BD Biosciences, PerkinElmer and GE Healthcare have over the years introduced a wide range of products such as HCS imagers equipped with on board dispenser options and environment control chambers.
Major players profiled in the report include BD Biosciences, BioTek Instruments Inc., CompuCyte Corporation, CM Technologies Oy, Definiens AG, EMD Millipore, EVOTEC BioSystems, Essen BioScience, Fluxion Biosciences, Inc., GE Healthcare Life Sciences, Genedata AG, IntelliCyt Corporation, Life Technologies Corporation, Molecular Devices Inc., PerkinElmer Inc., Roche Applied Sciences, Thermo Fisher Scientific, Inc., TTP LabTech Ltd., and Yokogawa Electric Corporation.
The research report titled “High Content Screening (HCS): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the global market, industry and product/technology overview, competitive scenario, key growth drivers, recent industry activity, product launches and profiles of major/niche global as well as regional market participants. The report provides annual revenue estimates and projections for high content screening market for the years 2010 through 2018 for the following geographic markets – US, Canada, Japan, Europe and Rest of World. The report also provides a historic analysis for the years 2004 through 2009 for additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/